RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts

MARLBOROUGH, Mass., Sept. 6, 2017 -- (Healthcare Sales & Marketing Network) -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today announced t... Biopharmaceuticals, Dermatology RXi Pharmaceuticals, Samcyprone, cutaneous warts
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news